JMJD2A (KDM4A) Homogeneous Assay Kit

Catalog #
50413
$1,875 *
Size: 384 reactions
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The JMJD2A (KDM4A) Homogeneous Assay Kit is designed to measure JMJD2A (Jumonji domain-containing protein 2A) activity for screening and profiling applications. The JMJD2A (KDM4A) Homogeneous Assay Kit comes in a convenient 384-well AlphaLISA® format, with enough purified recombinant JMJD2A (amino acids 1-350), substrate, primary antibody, assay and detection buffer for 384 enzyme reactions.

Figure 1: JMJD2A Homogenous Assay Kit schematic.
A sample containing JMJD2A is incubated with a substrate. This is followed by the addition of acceptor beads and primary antibody, and finally donor beads. Alpha-counts are then counted. Alpha-counts are proportional to JMJD2A demethylase activity.

Need us to run inhibitor screens or profile your compounds against JMJD2A (KDM4A)? Check out our Demethylase Screening Services.

This product has been cited 5 times.

Synonyms
JMJD2A, JHDM3A, KDM4A
Product Info
Storage and Usage
Citations5
Assay Kit Format
AlphaLISA®
Materials Required But Not Supplied
  •  AlphaLISA® anti-mouse IgG acceptor beads, 5 mg/ml (Perkin Elmer #AL105C)
  •  AlphaScreen® Streptavidin-conjugated donor beads, 5 mg/ml (Perkin Elmer #6760002S)
  •  Optiplate - 384 (Perkin Elmer #60072900
  •  AlphaScreen® microplate reader
Format
Catalog #  Name Amount Storage 
50123 JMJD2B (KDM4A (1-350), His-Tag* 60 μg -80°C
52140E Primary Antibody 5 20 µl -80°C
  Biotinylated Histone H3 Peptide Substrate 500 reactions -80°C
52409 4x HDM Assay Buffer 4 3 x 1 ml -80°C
52031 4x Detection Buffer  2 ml -20°C

 

 

 

 

 

 

 

 

 

*The initial concentration of enzyme is lot-specific and will be indicated on the tube containing the protein.

UniProt #
O75164
Background

JMJD2A (Jumonji domain -containing protein 2A), also known as KDM4A, belongs to the JMJD2 subfamily of JMJD histone lysine demethylase proteins. It is involved in demethylating H3K9me2/3, H3K4me2/3, H3K36me2/3, K3K23me2/3 and H4K20me2/3, participating in DNA damage response and transcription. JMJD2A is found at high levels in different cancer types, such as breast, gastric, ovarian, and liver cancer. In bladder cancer, the high levels of JMJD2A induce EMT (epithelial-mesenchymal transition) through its effect on SLUG expression.  The use of JMJD2A inhibitors is an area of interest that requires further development, and the development of active inhibitors will be beneficial in the cancer therapy field.

References

Manni W., et al., 2022 Signal Transduct Target Ther 7:304.
Parkinson J., et al., 2023 Proteins 91(10):32-46.